Novel oral anticoagulants including the factor Xa inhibitor rivaroxaban are important alternatives to warfarin for the prevention of thromboembolic stroke in patients with nonvalvular atrial fibrillation. The pharmacology and metabolism of these agents differ from those of the vitamin K antagonists used over the decades preceding their introduction. We present a case of spontaneous hemopericardium and cardiac tamponade following administration of rivaroxaban. A review of the patient's medications revealed a total of seven agents known to be metabolized through cytochrome P450 3A4 (CYP3A4), the major pathway for rivaroxaban metabolism. While most physicians are familiar with recommendations to monitor renal function in patients prescribed rivaroxaban, we suspect that many fail to evaluate possible interactions with other agents having CYP3A4 inhibitory or inducer activity. W e report a case of pericardial tamponade requiring emergent pericardiocentesis occurring soon after rivaroxaban therapy was started in a patient taking seven medications metabolized by the same cytochrome pathway as rivaroxaban. Th e potential for interference of rivaroxaban metabolism has not been appreciated to the same extent as the interference of multiple medications with warfarin metabolism.
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CASE REPORT
A 69-year-old man with hypertension and hyperlipidemia presented to the emergency department with palpitations and chest discomfort and was found to have paroxysmal atrial fibrillation (AF) with a rapid ventricular response. Th e AF terminated spontaneously with rate control, and the patient had no further chest discomfort. Echocardiography showed normal cardiac structure and function. Coronary angiography revealed no signifi cant coronary artery disease. Th e patient was treated with dronedarone 400 mg twice daily and rivaroxaban 20 mg daily based on a calculated CHADSVASC 2 score of 3 (age, diabetes mellitus, and hypertension) and HAS-BLED score of 3. At the time of initiation of rivaroxaban, the patient's serum creatinine level and glomerular fi ltration rate were 1.00 mg/dL and >60 mL/min/1.73 m 2 , respectively.
Th ree days after starting rivaroxaban, the patient returned to the hospital with tachycardia, hypotension, and syncope. 
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Denisse Menendez , MD , and Jeffrey Michel , MD His electrocardiogram showed sinus tachycardia, and an echocardiogram revealed a large pericardial eff usion with fi ndings suggesting tamponade. Emergency pericardiocentesis was performed, during which 1400 mL of bloody fl uid was removed with improvement in his hemodynamics. His rivaroxaban was discontinued. A pericardial drain was left in place, and over the next 48 hours there was minimal residual serosanguinous drainage. Cultures, including staining for acid-fast bacilli, were negative, as were cytological test results. Computed tomography imaging showed no evidence of pericardial thickening, granulomatous disease, or active bleeding into the pericardium. Th ere was minimal infl ammation, which was attributed to the indwelling drain. Th e computed tomography images also showed no evidence of pericarditis. Th e drain was removed and the patient was observed for 24 hours. Repeat echocardiography demonstrated a small residual pericardial eff usion without evidence of tamponade. He was discharged to home and made a full recovery.
A review of the patient's medical regimen revealed seven medications known to undergo metabolism via cytochrome P450 3A4 (CYP3A4), including rivaroxaban, omeprazole, atorvastatin, dronedarone, tamsulosin, and tadalafi l ( Table 1 ) ( 1 ). Th e patient has been followed in the clinic monthly for the last 2 months to ensure resolution of pericardial eff usion. At this time, he has opted to not reinitiate anticoagulation but rather to take aspirin 325 mg daily for stroke prevention in AF.
DISCUSSION
It appears that our patient experienced spontaneous pericardial bleeding associated with use of rivaroxaban. We found only one published report of unexplained spontaneous cardiac tamponade associated with rivaroxaban use ( 2 ). While renal excretion of rivaroxaban and other novel oral anticoagulants is well known, there is less appreciation of their hepatic metabolism. For rivaroxaban, hepatic metabolism primarily through CYP3A4 accounts for most (65%) of the drug's elimination. Hemopericardium with tamponade following rivaroxaban administration and its attenuation by CYP3A4 inhibitors October 2016
Reduction in rivaroxaban dosing is recommended in patients with mild to moderate renal impairment ( 3 ), and its use is not recommended in patients with severe renal impairment. Th ere are no guidelines to assist patients or physicians in adjusting dosing based on patient use of other agents that undergo CYP3A4 metabolism.
Pharmacologic studies have demonstrated that single agents with CYP3A4 inhibitor activity such as ketoconazole can increase serum rivaroxaban levels by as much as 158% ( 4 ). Few studies have investigated the interaction of other CYP3A4 metabolized drugs with rivaroxaban in clinical practice. One of the few large studies investigating possible drug-drug interactions included 17,701 individuals receiving rivaroxaban for thromboprophylaxis after orthopedic surgery ( 5 ). Th is study reported no association but included few individuals taking medications that act as inhibitors of CYP3A4 (<3%). We suspect that patients receiving medical therapy for nonvalvular AF are more likely to be on agents with known CYP3A4 inhibitory activity. Diltiazem, verapamil, and dronedarone are potent inhibitors of CYP3A4 and are used with anticoagulants in patients with AF. Omeprazole, tadalafi l, and tamsulosin are commonly used agents in older patients prone to develop AF.
We suspect that the coadministration of multiple drugs metabolized by CYP3A4 led to elevated serum levels of rivaroxaban, which in turn was the major causative factor for the patient's pericardial bleeding. Novel oral anticoagulants have diff ering pharmacologic profi les ( Table 2 ) ( 6 ), with both apixaban and rivaroxaban having signifi cant hepatic metabolism through CYP3A4. We hope that our case can serve as a reminder that physicians should exercise caution when prescribing rivaroxaban in combination with other agents that share CYP3A4 metabolism. Omega-3 fatty acids 2 g QD No † One of several pathways. * While not generally considered to be a CYP3A4 inhibitor, the metabolite N-desisopropyl metoprolol has been shown to have inhibitory activity in vitro ( 1 ). BID indicates twice a day; PRN, as needed; QD, once a day; TID, three times a day.
